ABBVIE INC (ABBV) Stock News

USA - NYSE:ABBV - US00287Y1091 - Common Stock

227.99 USD

-0.26 (-0.11%)

Last: 10/24/2025, 8:07:35 PM

228 USD

0.01 (0%)

After Hours: 10/24/2025, 8:07:35 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ABBV Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: The Motley Fool - Mentions: OKE CVX XOM JPM ...

ONEOK’s 6% Dividend Draws Smart Money Despite a Nearly 30% Drop

2 days ago - By: The Motley Fool - Mentions: JPM CVX MRK STT ...

Why Some Investors Are Taking Profits on JPMorgan After Its Big Rally

12 days ago - By: Benzinga

If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today

20 days ago - By: Benzinga

AbbVie's Botox Shows Improvement In Movement Disorder Study

5 days ago - By: AbbVie

The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients

6 days ago - By: Zacks Investment Research - Mentions: AZN PFE MRK

Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings

6 days ago - By: AbbVie

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor

9 days ago - By: Stocktwits - Mentions: NVO

Novo Nordisk Hires US Pharma Veteran After Trump Touts ‘Much Lower’ Prices Of Ozempic

9 days ago - By: AbbVie

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

13 days ago - By: Zacks Investment Research - Mentions: AZN PFE LLY

AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve

13 days ago - By: Stocktwits - Mentions: JGRO DUHP

AbbVie Stock Rises After FDA Approves Changed Recommendations For Use Of Popular Rinvoq Drug

13 days ago - By: AbbVie

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

13 days ago - By: AbbVie

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors